Cargando…
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis (RA), via selective B lymphocyte depletion. Experience in oncology shows that rituximab is well t...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833440/ https://www.ncbi.nlm.nih.gov/pubmed/15180892 http://dx.doi.org/10.1186/ar1008 |